B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and operational challenges.

Trading Advice for Viking Therapeutics Inc. VKTX including day trading swing trading and long term investing plans for VKTX ...